Abstract 10368: The Safety and Tolerability of Prolonged Inhalation of Hydrogen Gas in Air: A Phase I Clinical Trial
Alexis Cole, Francesca Sperotto, Stephanie Carlisle-Larsen, Michael J Rivkin, James A Dinardo, John N Kheir · Circulation · 2021
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
Abstract 10368: The Safety and Tolerability of Prolonged Inhalation of Hydrogen Gas in Air: A Phase I Clinical Trial There were no significant changes in PFTs (B), MMSE scores (C), EKG measurements (D) or serologic tests for hematologic (except for clinically-insignificant increases in hematocrit and platelet counts), renal, hepatic, pancreatic, or cardiac injury (E) associated with H₂ inhalation.
What the Researchers Studied
The study examined 8 healthy participants.
How Molecular Hydrogen Was Used
Molecular hydrogen was administered as following fda and irb approval of this investigator-initiated phase i ind study (nct04046211), 8 healthy participants underwent hospitalized exposure to 2.4% h₂ in medical air via high flow nasal cannula (15 lpm) for either 24 hours (n=2), 48 hours (n=2), or 72 hours (n=4).
What the Researchers Found
There were no significant changes in PFTs (B), MMSE scores (C), EKG measurements (D) or serologic tests for hematologic (except for clinically-insignificant increases in hematocrit and platelet counts), renal, hepatic, pancreatic, or cardiac injury (E) associated with H₂ inhalation.
H₂ Mechanisms / Biological Findings
The source material reviewed did not establish a specific molecular hydrogen mechanism for the reported findings.
Authors’ Conclusion
These data will be foundational to future interventional studies of inhaled H₂ in injury states, including following cardiac arrest.